Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00943 |
| Species: | Homo sapiens |
| Position : | chr4:55859107-55860311 |
| Year: | 2018 |
| Title: | AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| PMID: | 29236325 |
| Cell Source: | Kasumi-1,U937-AE |
| Experiment Type: | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| Low Throughput Method: | Luciferase reporter assay; Reporter assay; ChIP-qPCR/ChIP; 3C; RT-qPCR/qPCR; RNAi/siRNA/shRNA |
| Target gene : | KIT |
| TF name : | RUNX1 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| RUNX1 | AndrogenReceptor | netpath | 167 |
| RUNX1 | Organic cation transport | reactome | 9 |
| RUNX1 | RANKL | netpath | 84 |
| RUNX1 | Regulation of nuclear SMAD2/3 signaling | pid | 82 |
| RUNX1 | TGF_beta_Receptor | netpath | 220 |
| RUNX1 | Validated transcriptional targets of deltaNp63 isoforms | pid | 47 |
| RUNX1 | Pathways in cancer | kegg | 321 |
| RUNX1 | Chronic myeloid leukemia | kegg | 69 |
| RUNX1 | Acute myeloid leukemia | kegg | 53 |